Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management.

Introduction: In recognition of the value of long-term real-world data, a postauthorization safety study of the inhaled corticosteroid (ICS) fluticasone propionate and long-acting β-agonist (LABA) formoterol fumarate (fluticasone/formoterol; Flutiform) was conducted.

Methods: This was a 12-month observational study of outpatients with asthma aged ⩾ 12 years in eight European countries. Patients were prescribed fluticasone/formoterol according to the licensed indication, and independently of their subsequent enrolment in the study.